248.00p-11.00 (-4.25%)06 Mar 2025, 16:35
Jump to:
Hutchmed (China) Limited Fundamentals
Company Name | Hutchmed (China) Limited | Last Updated | 2025-03-06 |
---|---|---|---|
Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
Shares in Issue | 854.681 m | Market Cap | £2.12 bn |
PE Ratio | 30.22 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | $0.12 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0.0651 | Debt Equity Ratio | 0.0752 |
Asset Equity Ratio | 1.6766 | Cash Equity Ratio | 1.0671 |
Quick Ratio | 2.6610 | Current Ratio | 2.81 |
Price To Book Value | 3.8256 | ROCE | 0 |
Hutchmed (China) Limited Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Hutchmed (China) Limited Company Financials
Assets | 2023 | 2022 |
---|---|---|
Tangible Assets | $104.39 m | $84.67 m |
Intangible Assets | 0 | 0 |
Investments | $48.41 m | $73.78 m |
Total Fixed Assets | $182.93 m | $189.56 m |
Stocks | $50.26 m | $56.69 m |
Debtors | $149.91 m | $127.17 m |
Cash & Equivalents | $886.34 m | $631.00 m |
Other Assets | 0 | 0 |
Total Assets | $1.28 bn | $1.03 bn |
Liabilities | 2023 | 2022 |
---|---|---|
Creditors within 1 year | $403.03 m | $353.90 m |
Creditors after 1 year | $133.36 m | $38.67 m |
Other Liabilities | 0 | 0 |
Total Liabilities | $536.39 m | $392.57 m |
Net assets | $743.39 m | $636.87 m |
Equity | 2023 | 2022 |
---|---|---|
Called up share capital | $87.13 m | $86.48 m |
Share Premium | $1.52 bn | $1.50 bn |
Profit / Loss | $58.31 m | -$410.42 m |
Other Equity | $730.54 m | $610.37 m |
Preference & Minorities | $12.85 m | $26.50 m |
Total Capital Employed | $743.39 m | $636.87 m |
Ratios | 2023 | 2022 |
---|---|---|
Debt Ratio | $0.07 | $0.04 |
Debt-to-Equity | $0.07 | $0.04 |
Assets / Equity | 1.6766 | 1.6766 |
Cash / Equity | 1.0671 | 1.0671 |
EPS | $0.13 | -$0.43 |
Cash Flow | 2023 | 2022 |
---|---|---|
Cash from operating activities | $219.26 m | -$268.60 m |
Cashflow before financing | $267.92 m | -$351.36 m |
Increase in Cash | -$23.22 m | -$54.77 m |
Income | 2023 | 2022 |
---|---|---|
Turnover | $838.00 m | $426.41 m |
Cost of sales | $384.45 m | $311.10 m |
Gross Profit | $453.55 m | $115.31 m |
Operating Profit | 0 | 0 |
Pre-Tax profit | $58.31 m | -$410.42 m |
Hutchmed (China) Limited Company Background
Sector | Healthcare |
---|---|
Activities | HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
Latest Interim Date | 31 Jul 2024 |
Latest Fiscal Year End Date | 19 Mar 2025 |
Hutchmed (China) Limited Directors
Appointed | Name | Position |
---|---|---|
2024-10-21 | Mr. Graeme Allan Jack | Non-Executive Director |
2024-10-21 | Mr. Dan Eldar | Non-Executive Director,Chairman |
2024-04-08 | Ms. Edith Shih | Non-Executive Director,Company Secretary |
2024-10-21 | Mr. Paul Rutherford Carter | Non-Executive Director,Senior Independent Director |
2017-02-01 | Mr. Christopher John Nash | Director |
2024-05-17 | Mr. Chi Keung Simon To | Executive Director,Chairman |
2022-03-03 | Mr. Christian Hogg | Executive Director,Chief Executive Officer |
2017-03-01 | Mr. Michael William Davis Howell | Director |
2017-02-01 | Professor Christopher Huang | Non-Executive Director |
2024-03-05 | Mr. Johnny Cheng Chig FUNG | Executive Director,Chief Financial Officer |
2023-05-12 | Dr. Karen Jean Ferrante, M.D. | Non-Executive Director |
2024-08-06 | Dr. Weiguo Su | Executive Director,Chief Executive Officer and Chief Scientific Officer |
2024-10-21 | Professor Shu Kam Tony Mok | Non-Executive Director |
2024-05-08 | Dr. Renu Bhatia | Non-Executive Director |
Hutchmed (China) Limited Contact Details
Company Name | HUTCHMED (China) Ltd |
---|---|
Address | Ugland House, P.O. Box 309, Grand Cayman, KY1-1104 |
Telephone | +852 21281188 |
Website | https://www.hutch-med.com |
Hutchmed (China) Limited Advisors
Financial PR Adviser | BMC Communications |
---|---|
Phone | +1 646 513-3125 |
Financial PR Adviser | The Trout Group |
---|---|
Phone | +86 15821996861 |
Fax | +86 16463782901 |
Registrar | Computershare Investor Services Ltd |
---|---|
Phone | +44 8707074040 |
Fax | +44 3708735851 |
Auditor | PricewaterhouseCoopers |
---|---|
Phone | +852 22898888 |
Fax | +852 28109888 |
Stockbroker | Panmure Gordon (UK) Ltd |
---|---|
Phone | +44 2078862500 |
Stockbroker | UBS Limited |
---|---|
Phone | +44 2075678000 |
Solicitor | DLA Piper LLP |
---|---|
Phone | +44 8700111111 |
Fax | +44 2077966666 |
Financial PR Adviser | Citigate Dewe Rogerson |
---|---|
Phone | +44 2076389571 |
Nominated Adviser | Panmure Gordon (UK) Ltd |
---|---|
Phone | +44 2078862500 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine

Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Schroders PLC | 428.20 | 12.62 |
Itv PLC | 76.35 | 9.70 |
Rhi Magnesita N.V. | 3,800.00 | 9.67 |
Qinetiq Group PLC | 530.00 | 7.37 |
Victrex PLC | 1,012.00 | 6.98 |
Admiral Group PLC | 3,046.00 | 5.00 |
Fallers
Company | Price | % Chg |
---|---|---|
Melrose Industries PLC | 556.40 | -18.18 |
Spire Healthcare Group PLC | 188.60 | -15.99 |
Harbour Energy PLC | 189.40 | -11.50 |
Rentokil Initial PLC | 346.20 | -10.77 |
Hunting PLC | 286.50 | -6.68 |
Ithaca Energy PLC | 126.00 | -6.67 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.